RESUMEN
Porcine circovirus type 2 (PCV2) systemic disease is currently considered one of the most relevant infectious diseases in swine industry worldwide from an economical point of view. Although piglets generally become diseased between 8 and 16 weeks of age, they can be infected much earlier, even already in utero. However, data on the prevalence of PCV2 infection in newborn piglets are very variable (lower than 40 up to 82%) and most of the studies have been performed in US. In European pig farms, using group-housing systems for gestating sows, a different herd PCV2 infection and immunological status may be expected and was recently reported in Germany. If that is the current scenario in most European farms, strategies to prevent horizontal transmission become essential for the control of the infection. The aim of our study was to determine the PCV2 prevalence in newborn piglets on 4 endemically infected farms in the Netherlands under European conditions. Eleven sows and 8 piglets per litter from 4 farms selected by their assumed PCV2 endemic infection status were sampled. Plasma from piglets was analysed with a PCV2 qPCR and serum from the sows was analysed with a commercial circovirus IgG ELSIA, circovirus IgM ELISA and PCV2 qPCR. In none of the samples from the piglets PCV2 was detected by the qPCR. None of the samples from the sows tested positive in the qPCR and circovirus IgM ELISA. The true- and apparent prevalence of IgG at herd and sow level were 0.75 and 0.81 and, 0.30 and 0.32, respectively, and no statistically significant association with sow parity was observed. These results reveal a very low prevalence of PCV2 in newborn piglets on endemically infected farms in The Netherlands, opening the opportunity of re-evaluation of the control measures applied in these farms.
Asunto(s)
Animales Recién Nacidos , Anticuerpos Antivirales/sangre , Infecciones por Circoviridae/veterinaria , Enfermedades de los Porcinos/epidemiología , Viremia/veterinaria , Animales , Infecciones por Circoviridae/epidemiología , Circovirus/inmunología , Circovirus/aislamiento & purificación , Granjas , Femenino , Alemania , Países Bajos/epidemiología , Embarazo , Prevalencia , Porcinos , Viremia/epidemiologíaRESUMEN
Swine brucellosis caused by Brucella suis biovar 2 is an emerging disease in continental Europe. Without effective vaccines being available, the European Food Safety Authority (EFSA) recommends the full depopulation of infected herds as the only strategy to eradicate B. suis outbreaks. Using data collected from 8 herds suffering natural swine brucellosis outbreaks, we assessed the efficacy of four control strategies: (i) oxytetracycline treatment only, as a default scenario, (ii) oxytetracycline treatment combined with skin testing and removal of positive animals, (iii) oxytetracycline treatment combined with serological testing (Rose Bengal test-RBT-and indirect ELISA -iELISA-) and removal of seropositive animals and (iv) oxytetracycline treatment combined with both serological (RBT/iELISA) and skin testing and removal of positive animals. A Susceptible-Infectious-Removal model was used to estimate the reproduction ratio (R) for each strategy. According to this model, the oxytetracycline treatment alone was not effective enough to eradicate the infection. However, this antibiotic treatment combined with diagnostic testing at 4-monthly intervals plus immediate removal of positive animals showed to be effective to eradicate brucellosis independent of the diagnostic test strategy used in an acceptable time interval (1-2 years), depending on the initial number of infected animals.
Asunto(s)
Sacrificio de Animales , Antibacterianos/uso terapéutico , Brucelosis/veterinaria , Oxitetraciclina/uso terapéutico , Enfermedades de los Porcinos/prevención & control , Agricultura , Animales , Brucelosis/tratamiento farmacológico , Brucelosis/prevención & control , Terapia Combinada/veterinaria , Enfermedades Transmisibles Emergentes/tratamiento farmacológico , Enfermedades Transmisibles Emergentes/prevención & control , Enfermedades Transmisibles Emergentes/veterinaria , Erradicación de la Enfermedad/métodos , Europa (Continente) , Porcinos , Enfermedades de los Porcinos/tratamiento farmacológicoRESUMEN
Swine brucellosis caused by Brucella suis biovar 2 is an emerging disease in Europe. Currently used diagnostic tests for swine brucellosis detect antibodies to the O-polysaccharide (O-PS) of Brucella smooth lipopolysaccharide (S-LPS) but their specificity is compromised by false-positive serological reactions (FPSRs) when bacteria carrying cross-reacting O-PS infect pigs. FPSRs occur throughout Europe, and the only tool available for a specific B. suis diagnosis is the intradermal test with Brucella protein extracts free of O-PS or S-LPS. Using sera of 162 sows naturally infected by B. suis biovar 2, 406 brucellosis-free sows, and 218 pigs of brucellosis-free farms affected by FPSR, we assessed the diagnostic performance of an indirect ELISA with rough LPS (thus devoid of O-PS) and of gel immunodiffusion, counterimmunoelectrophoresis, latex agglutination and indirect ELISA with O-PS free proteins in comparison with several S-LPS tests (Rose Bengal, complement fixation, gel immunodiffusion and indirect ELISA). When adjusted to 100% specificity, the sensitivity of the rough LPS ELISA was very low (30%), and adoption of other cut-offs resulted in poor specificity/sensitivity ratios. Although their specificity was 100%, the sensitivity of protein tests (ELISA, latex agglutination, counterimmunoelectrophoresis, and gel immunodiffusion) was only moderate (45, 58, 61 and 63%, respectively). Among S-LPS tests, gel immunodiffusion was the only test showing acceptable sensitivity/specificity (68 and 100%, respectively). Despite these shortcomings, and when the purpose is to screen out FPSR at herd level, gel immunodiffusion tests may offer a technically simple and practical alternative to intradermal testing.
Asunto(s)
Brucella suis/aislamiento & purificación , Brucelosis/veterinaria , Pruebas Serológicas/normas , Enfermedades de los Porcinos/diagnóstico , Animales , Brucelosis/diagnóstico , Pruebas de Fijación del Complemento , Contrainmunoelectroforesis , Reacciones Cruzadas , Ensayo de Inmunoadsorción Enzimática , Europa (Continente) , Reacciones Falso Positivas , Inmunodifusión , Pruebas Intradérmicas , Pruebas de Fijación de Látex , Rosa Bengala , Sensibilidad y Especificidad , PorcinosRESUMEN
The aim of this work was developing effective treatments against Brucella suis biovar 2, responsible for swine brucellosis in Europe. MICs for antibiotics used classically in brucellosis and two new macrolides (tulathromycin and tildipirosin) were determined for 33 B. suis biovar 2 field and B. suis reference strains. MIC90 values ranged from 0.01 to 0.25 µg/mL. The best candidates, given alone or combined, were then evaluated in mice. Ten groups (n = 7) of BALB/c mice were inoculated (1 × 10(5) CFU/mouse) with a virulent B. suis biovar 2 field strain. All groups, excepting untreated control, were treated for 14 days with, respectively, doxycycline, dihydrostreptomycin, tulathromycin (one or two doses), or tildipirosin (one or two doses) given alone, and doxycycline combined with dihydrostreptomycin, tulathromycin, or tildipirosin. Combined tildipirosin treatment was the most effective, then selected for pig studies. Sixteen B. suis biovar 2 naturally infected sows were treated with oxytetracycline (20 mg/kg BW/daily) for 21 days. The half of these received also tildipirosin (4 mg/kg BW) in two doses with a 10-day interval. An extensive bacteriological study conducted ten days after ceasing treatments proved the efficacy of this combined oxytetracycline/tildipirosin treatment.
Asunto(s)
Antibacterianos/uso terapéutico , Brucelosis/veterinaria , Disacáridos/uso terapéutico , Compuestos Heterocíclicos/uso terapéutico , Enfermedades de los Porcinos/tratamiento farmacológico , Tilosina/análogos & derivados , Animales , Brucella suis , Brucelosis/tratamiento farmacológico , Brucelosis/microbiología , Quimioterapia Combinada , Femenino , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Oxitetraciclina/administración & dosificación , Oxitetraciclina/uso terapéutico , Porcinos , Enfermedades de los Porcinos/microbiología , Tilosina/administración & dosificación , Tilosina/uso terapéuticoRESUMEN
Current serological tests for swine brucellosis detect antibodies to the Brucella O-polysaccharide (O/PS). However, when infections by bacteria carrying cross-reacting O/PS occur, these tests suffer from false positive serological reactions (FPSR), and the skin test with Brucella soluble protein extracts is the best diagnostic alternative to differentiate true Brucella suis infections from FPSR in pigs. Since this test has been seldom used in B. suis infected swine, the clinical and histological features involved have not been described properly. Here, we describe the clinical and histological events in B. suis biovar 2 infected pigs skin tested with a cytosoluble O/PS free protein extract from rough Brucella abortus Tn5::per mutant. A similar extract from rough Ochrobactrum intermedium was also used for comparative purposes. No relevant differences were evidenced between the homologous and heterologous allergens, and the main clinical feature was an elevated area of the skin showing different induration degrees. Moreover, an important vascular reaction with hyperemia and haemorrhage was produced in most infected sows 24-48 h after inoculation, thus facilitating the clinical interpretation of positive reactions. Histologically, combined immediate (type III) and delayed (type IV) hypersensitivity reactions were identified as the most relevant feature of the inflammatory responses produced.
Asunto(s)
Antígenos Bacterianos , Brucella suis , Brucelosis/veterinaria , Enfermedades de los Porcinos/patología , Animales , Antígenos Bacterianos/inmunología , Brucella abortus/inmunología , Brucella suis/inmunología , Brucelosis/diagnóstico , Brucelosis/inmunología , Brucelosis/patología , Reacciones Cruzadas/inmunología , Reacciones Falso Positivas , Femenino , Infecciones por Bacterias Gramnegativas/diagnóstico , Infecciones por Bacterias Gramnegativas/inmunología , Infecciones por Bacterias Gramnegativas/veterinaria , Ochrobactrum/inmunología , Piel/inmunología , Piel/patología , Pruebas Cutáneas/veterinaria , Porcinos/inmunología , Porcinos/microbiología , Enfermedades de los Porcinos/diagnóstico , Enfermedades de los Porcinos/inmunología , Enfermedades de los Porcinos/microbiologíaRESUMEN
Swine brucellosis by Brucella suis biovar 2 is an emerging disease whose control is based on serological testing and culling. However, current serological tests detect antibodies to the O-polysaccharide (O/PS) moiety of Brucella smooth lipopolysaccharide (S-LPS), and thus lack specificity when infections by Yersinia enterocolitica O:9 and other gram-negative bacteria carrying cross-reacting O/PS occur. The skin test with the protein-rich brucellin extract obtained from rough B. melitensis B115 is assumed to be specific for discriminating these false positive serological reactions (FPSR). However, B115 strain, although unable to synthesize S-LPS, accumulates O/PS internally, which could cause diagnostic problems. Since the brucellin skin test has been seldom used in pigs and FPSR are common in these animals, we assessed its performance using cytosoluble protein extracts obtained from B. abortus rough mutants in manBcore or per genes (critical for O/PS biosynthesis) and B. melitensis B115. The diagnostic sensitivity and specificity were determined in B. suis biovar 2 culture positive and brucellosis free sows, and apparent prevalence in sows of unknown individual bacteriological and serological status belonging to B. suis biovar 2 naturally infected herds. Moreover, the specificity in discriminating brucellosis from FPSR was assessed in brucellosis free boars showing FPSR. The skin test with B. abortus ΔmanBcore and B. melitensis B115 allergens performed similarly, and the former one resulted in 100% specificity when testing animals showing FPSR in indirect ELISA, Rose Bengal and complement fixation serological tests. We conclude that O/PS-free genetically defined mutants represent an appropriate alternative to obtain Brucella protein extracts for diagnosing swine brucellosis.